RPL31

Across TCGA pan-cancer cohorts, RPL31 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPL31’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where RPL31 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RPL31 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

PDAC, LUAD, and COAD are the cancer types where RPL31 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL31 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	−1.226	<.001	9	view →
LUAD	Male	III,IV	+0.591	<.001	9	view →
COAD	Female	III,IV	+0.367	<.001	9	view →
HNSC	All	IV	−0.348	<.001	8	view →
LSCC	Male	II,III,IV	+0.343	<.001	8	view →
CCRCC	All	II,III,IV	+0.255	<.001	8	view →
OV	All	All	+0.550	.021	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPL31–PDAC

Open the PDAC breakdown →